1. CAMCEVI 42 mg
2. CAMCEVI 21 mg
3. FP-025
4. FP-045
5. Aderamastat (FP-025) Phase 2 Study

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

AP BIOSCIENCES INC. primarily focuses on the development of early-stage drug candidates through to preclinical trials, utilizing drug design and its two existing technology platforms to individually develop distinct monoclonal or bispecific antibody drugs tailored to promising targets, mechanisms of action, and disease characteristics.
AP BIOSCIENCES INC. possesses two technology platforms, both of which were independently developed by AP BIOSCIENCES INC. with full patent ownership:
1. OmniMab Library (Fully Human Antibody Library)
2. Target-Directed T-Cell Activation 3T Platform (T-cube Bispecific Antibody Platform)
New Drug R&D Products:
1. IBI302 (Anti-VEGF and Anti-Complement Bifunctional Recombinant Protein)
2. AP505/B1962 (PD-L1 x VEGF Bispecific Antibody)
3. AP203 (PD-L1 x CD137 Fully Human Bispecific Antibody)
4. AP402 (HER2v x CD137 Fully Human Bispecific Antibody)
5. AP601 (CD73 x CD137 Fully Human Bispecific Antibody)
(The content above was translated by AI.)

Utilizing transposase for stable clone establishment, CHIMERA BIOSCIENCE INC.’s method offers higher safety, stability, and yield compared to current mainstream antibiotic selection or lentiviral methods. This approach is highly suitable for peptide therapeutics, including recombinant proteins and antibody drugs. Through CHIMERA BIOSCIENCE INC.’s collaboration with Bora Biologics, the established stable clones can be transitioned to Bora Biologics for industrial-scale protein production.

CHIMERA BIOSCIENCE INC. also develops viral gene delivery systems for cell and gene therapies, including adenovirus-based transposase/CRISPR-Cas editing systems and industrial-grade manufacturing processes for adeno-associated virus (AAV).

For monoclonal antibody production, CHIMERA BIOSCIENCE INC. goes beyond traditional hybridoma technology. We can perform direct screening from B cells following antigen-induced immune responses. Alternatively, we can construct phage display libraries from antibody VAB fragments for direct screening against target antigens. Furthermore, this process can directly generate CHO cell lines to facilitate subsequent scale-up production, significantly shortening development timelines and reducing costs.

Other core expertise of CHIMERA BIOSCIENCE INC. includes CRISPR/Cas gene editing, recombineering systems based on homologous recombination principles, and phage display library construction and screening for the identification of peptide drug candidate leads.
(The content above was translated by AI.)